標(biāo)題: Titlebook: Colorectal Cancer; Evidence-based Chemo Maurie Markman,Leonard B. Saltz Book 2007 Humana Press 2007 angiogenesis.cancer.cancer treatment.co [打印本頁] 作者: 實體 時間: 2025-3-21 16:17
書目名稱Colorectal Cancer影響因子(影響力)
書目名稱Colorectal Cancer影響因子(影響力)學(xué)科排名
書目名稱Colorectal Cancer網(wǎng)絡(luò)公開度
書目名稱Colorectal Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Colorectal Cancer被引頻次
書目名稱Colorectal Cancer被引頻次學(xué)科排名
書目名稱Colorectal Cancer年度引用
書目名稱Colorectal Cancer年度引用學(xué)科排名
書目名稱Colorectal Cancer讀者反饋
書目名稱Colorectal Cancer讀者反饋學(xué)科排名
作者: 低位的人或事 時間: 2025-3-21 21:30 作者: HAUNT 時間: 2025-3-22 04:27
Hervé De Bisschop,Serge Leblanc with hereditary cancer syndromes such as familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer should be referred for genetic counseling and offered appropriate genetic testing and specialized screening recommendations.作者: 使無效 時間: 2025-3-22 07:33
Book 2007g, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown s作者: 射手座 時間: 2025-3-22 10:16
2364-1134 . Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an ar作者: 圖表證明 時間: 2025-3-22 14:01 作者: 圖表證明 時間: 2025-3-22 19:40 作者: GOUGE 時間: 2025-3-22 22:51 作者: 饒舌的人 時間: 2025-3-23 01:47
Rationale for Adjuvant and Neoadjuvant Chemotherapy in the Resection of Liver Metastases,ddress the value of surgery in the setting of resectable liver metastasis; in fact, such trials would be unethical. Methods to improve resectability of metastases and long-term outcome utilizing chemotherapy are explored in this chapter.作者: stress-response 時間: 2025-3-23 06:41
Nursing Issues in Colorectal Cancer Chemotherapy,ociated toxicity profiles, and the tools used in symptom management, in order to maximally enhance the patient’s safety while receiving chemotherapy, and improve the patient’s overall quality of life.作者: 吹氣 時間: 2025-3-23 11:12 作者: 名次后綴 時間: 2025-3-23 14:15 作者: Graphite 時間: 2025-3-23 21:49
Adjuvant Chemotherapy for Colon Cancer,ved adjuvant 5-FU-based therapy effective, discuss controversies in adjuvant therapy, review recent trials with additional agents, and finally discuss the potential for molecular markers to augment stage in determining risk and response to therapy.作者: 老巫婆 時間: 2025-3-23 22:54 作者: impaction 時間: 2025-3-24 06:18
Book 2007 the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.作者: 確保 時間: 2025-3-24 07:34
https://doi.org/10.1007/978-3-662-09906-3ociated toxicity profiles, and the tools used in symptom management, in order to maximally enhance the patient’s safety while receiving chemotherapy, and improve the patient’s overall quality of life.作者: Unsaturated-Fat 時間: 2025-3-24 12:10 作者: 比喻好 時間: 2025-3-24 18:18
https://doi.org/10.1007/978-3-662-09906-3se preoperative chemoradiotherapy. In clinical trials in which these treatments were used in addition to surgery, improvements in local recurrence rates have been observed, although overall survival has less frequently been prolonged. These patients should also receive postoperative adjuvant chemotherapy.作者: 廣大 時間: 2025-3-24 21:06 作者: fallible 時間: 2025-3-24 23:22 作者: 立即 時間: 2025-3-25 04:14 作者: 惹人反感 時間: 2025-3-25 10:04
Percutaneous Radiofrequency Ablation in the Management of Patients With Colorectal Cancer, to treat patients with a single larger lesion, or in other instances where the objective is palliation rather than “cure. ” Technical issues that make some lesions treatable and other similar lesions not are outlined. The use of ablative therapies in other areas of the body such as lung and bone are also discussed.作者: optional 時間: 2025-3-25 15:21
Maurie Markman,Leonard B. SaltzIncludes supplementary material: 作者: adulterant 時間: 2025-3-25 16:21
Current Clinical Oncologyhttp://image.papertrans.cn/c/image/229763.jpg作者: Anticonvulsants 時間: 2025-3-25 21:38
https://doi.org/10.1007/978-3-030-89567-9e result of the progressive accumulation of genetic and epigenetic alterations that lead to the transformation of normal colonic epithelium to colon adenocarcinoma. The loss of genomic stability is a key molecular and pathophysiological step in this process and serves to create a permissive environm作者: Coterminous 時間: 2025-3-26 02:13 作者: 可以任性 時間: 2025-3-26 05:30 作者: Laconic 時間: 2025-3-26 11:52 作者: 難解 時間: 2025-3-26 16:40 作者: stress-test 時間: 2025-3-26 17:56
https://doi.org/10.1007/978-3-642-88183-1ys that, when deregulated, can lead to malignant transformation. The EGFR has now become validated as a target for anticancer therapy, with both small-molecule tyrosine kinase inhibitors and monoclonal antibodies showing clinical activity in some cancers. The biology of EGFR and the clinical data su作者: ACE-inhibitor 時間: 2025-3-27 00:36
Expertensysteme und Simulationsmodelle,is influenced by many factors, such as the nature of the first-line therapy, the potential toxicity of one regimen vs another, and the overall goal of treatment for the patient. In this chapter, we focus our discussion on the therapeutic strategies that can be used in the treatment of colorectal can作者: MUTED 時間: 2025-3-27 04:06
Expertensysteme und Simulationsmodelle,d to pathological stage. The concept of adjuvant chemotherapy was conceived many years ago as a way of eradicating microscopic residual disease, and proven by randomized clinical trials in colon cancer in the 1980s. Since that time, many important trials have been completed, and both our understandi作者: 仔細(xì)檢查 時間: 2025-3-27 07:31
https://doi.org/10.1007/978-3-662-09906-3s chapter reviews the evidence from clinical trials for the use of various perioperative strategies based on radiotherapy, chemotherapy, or both in these patients, as well as discusses how these results may inform clinical practice. In particular, two treatment strategies that have been shown to be 作者: recede 時間: 2025-3-27 13:17 作者: 你敢命令 時間: 2025-3-27 14:23
Das Weltmodell von Forrester: WORLD II, microwave, cryo and radiofrequency currently in use, followed by a discussion of the potential use of these modalities in patients with colorectal cancer. The most common indication for thermal ablation in this group of patients is the treatment of metastatic disease to the liver. Ideal candidates作者: 預(yù)示 時間: 2025-3-27 20:43
Das Weltmodell von Forrester: WORLD IIof the presence or absence of recurrence in the surgically cured patient, and evaluation of the response or progression of disease in the patient with known metastatic cancer. This chapter explores the role of different imaging modalities in each of these scenarios.作者: Accomplish 時間: 2025-3-28 01:13
https://doi.org/10.1007/978-3-662-09906-3ddressing the patient’s concerns. In a collaborative practice, the oncology nurse is also directly responsible for the education of the patient in symptom management, especially during chemotherapy. It is imperative for the oncology nurse to be knowledgeable regarding the current regimens, their ass作者: monogamy 時間: 2025-3-28 02:47 作者: 裁決 時間: 2025-3-28 06:40
https://doi.org/10.1007/978-1-59745-215-1angiogenesis; cancer; cancer treatment; colon; colorectal cancer; imaging; liver; metastasis; metastatic dis作者: START 時間: 2025-3-28 12:32
Chemoprevention of Colorectal Cancer,ruption of β-catenin-mediated signaling in colon epithelial cells. The 1,2-dimethylhydrazine (DMH)/azoxymethane (AOM) model of chemically induced colorectal cancer (CRC) and the murine multiple intestinal neoplasia (Min) model have provided useful information about the efficacy of available chemoprevention agents for CRC.作者: Collision 時間: 2025-3-28 15:22 作者: DIS 時間: 2025-3-28 18:51 作者: 萬靈丹 時間: 2025-3-29 02:23
Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer,is influenced by many factors, such as the nature of the first-line therapy, the potential toxicity of one regimen vs another, and the overall goal of treatment for the patient. In this chapter, we focus our discussion on the therapeutic strategies that can be used in the treatment of colorectal cancer after the failure of first-line therapy.作者: Discrete 時間: 2025-3-29 04:22
Colorectal Cancer Imaging,of the presence or absence of recurrence in the surgically cured patient, and evaluation of the response or progression of disease in the patient with known metastatic cancer. This chapter explores the role of different imaging modalities in each of these scenarios.作者: justify 時間: 2025-3-29 10:15
Das Weltmodell von Forrester: WORLD IIPain management is a critical component of the treatment of advanced colorectal cancer. In this chapter, a set of core principles is outlined to assist in the diagnosis and treatment of most causes of pain in the colorectal cancer patient. An algorithmic approach is described to facilitate expeditious and efficacious treatment.作者: SPER 時間: 2025-3-29 14:53
Pain Management in the Colorectal Cancer Patient,Pain management is a critical component of the treatment of advanced colorectal cancer. In this chapter, a set of core principles is outlined to assist in the diagnosis and treatment of most causes of pain in the colorectal cancer patient. An algorithmic approach is described to facilitate expeditious and efficacious treatment.作者: Pedagogy 時間: 2025-3-29 18:04 作者: BAN 時間: 2025-3-29 21:00 作者: 檔案 時間: 2025-3-30 01:42 作者: 大方不好 時間: 2025-3-30 07:14
Philippe Fauquet-Alekhine,Nane Pehuet as a potential antineoplastic strategy began more than 30 yr ago, and numerous angiogenic growth factors have subsequently been identified in large bowel tumors. The most successful antiangiogenic strategy to date has focused on inhibiting vascular endothelial growth factor (VEGF).作者: 刪減 時間: 2025-3-30 10:31
Expertensysteme und Simulationsmodelle,is influenced by many factors, such as the nature of the first-line therapy, the potential toxicity of one regimen vs another, and the overall goal of treatment for the patient. In this chapter, we focus our discussion on the therapeutic strategies that can be used in the treatment of colorectal cancer after the failure of first-line therapy.作者: ineffectual 時間: 2025-3-30 14:11 作者: 發(fā)現(xiàn) 時間: 2025-3-30 18:42 作者: 易受騙 時間: 2025-3-30 23:32
Chemoprevention of Colorectal Cancer,ruption of β-catenin-mediated signaling in colon epithelial cells. The 1,2-dimethylhydrazine (DMH)/azoxymethane (AOM) model of chemically induced colorectal cancer (CRC) and the murine multiple intestinal neoplasia (Min) model have provided useful information about the efficacy of available chemopre作者: BOLUS 時間: 2025-3-31 04:07 作者: Heresy 時間: 2025-3-31 06:39
Cytotoxic Chemotherapy for Metastatic Colorectal Cancer,de the topoisomerase I inhibitor irinotecan, the third-generation platinum analog oxaliplatin, and the oral fluoropyrimidine capecitabine, in addition to the mainstay, fluorouracil. The use of these agents is discussed in this chapter.
